Welcome to our dedicated page for Beam Therapeutics SEC filings (Ticker: BEAM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beam Therapeutics Inc. filings document the regulatory record for a Nasdaq-listed biotechnology company developing base-editing genetic medicines. Its Form 8-K reports cover operating results, portfolio updates, senior secured credit facility terms, license and standby license arrangements for base-editing patent rights, board changes and Regulation FD presentations.
Proxy materials describe annual meeting matters, director elections, executive compensation, equity awards and stockholder voting procedures. The filings also identify Beam’s common stock, capital structure, material agreements and governance practices tied to its clinical-stage biotechnology business.
Beam Therapeutics President Giuseppe Ciaramella reported an automatic sale of 11,810 shares of common stock at $24.58 per share. The shares were sold to cover tax withholding obligations tied to previously granted restricted stock units and executed under a pre-arranged Rule 10b5-1 trading plan. After this transaction, he directly holds 218,406 shares of Beam Therapeutics common stock.
Bellon Christine reported acquisition or exercise transactions in this Form 4 filing.
Beam Therapeutics Inc. reported that Chief Legal Officer Christine Bellon received a grant of 20,000 restricted stock units (RSUs) of common stock on March 31, 2026. Each RSU equals one share and was granted at no cash cost to her.
The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the grant date, conditioned on her continued service with Beam. After this award, she holds 115,667 shares of Beam common stock directly, reflecting a routine, compensation-related equity grant rather than an open-market purchase.
Cavanagh Bethany J reported acquisition or exercise transactions in this Form 4 filing.
Beam Therapeutics reported that SVP, Finance and Treasurer Bethany J. Cavanagh received a grant of 20,000 restricted stock units under the company’s 2019 Equity Incentive Plan. Each RSU represents one share of common stock and vests in four equal annual installments, subject to continued service. Following this award, she holds 54,813 shares directly.
Simon Amy reported acquisition or exercise transactions in this Form 4 filing.
Beam Therapeutics Inc. granted Chief Medical Officer Amy Simon 31,750 restricted stock units (RSUs), each representing the right to receive one share of Beam common stock. The RSUs vest in four substantially equal annual installments on the first four anniversaries of the grant date, conditioned on her continued service. Following this award, she directly holds 109,114 shares of Beam common stock, reflecting a compensation-related equity grant rather than an open-market transaction.
Emany Sravan Kumar reported acquisition or exercise transactions in this Form 4 filing.
Beam Therapeutics reported that its Chief Financial Officer, Sravan Kumar Emany, received a grant of 31,750 shares of common stock in the form of restricted stock units under the company’s 2019 Equity Incentive Plan. These RSUs vest in four substantially equal annual installments, starting on the first anniversary of the grant date, if he continues serving at the company. Following this award, his directly held common stock position is 105,456 shares, reflecting compensation tied to long-term service and company performance.
Ciaramella Giuseppe reported acquisition or exercise transactions in this Form 4 filing.
Beam Therapeutics Inc. reported that President Giuseppe Ciaramella received an equity grant of 40,000 restricted stock units (RSUs) of common stock. Each RSU represents the right to receive one Beam share and will vest in four substantially equal annual installments, subject to his continued service. Following this award, he directly holds 230,216 shares of Beam common stock, including the RSUs.
Beam Therapeutics CEO John M. Evans reported multiple equity transactions in Beam Therapeutics Inc. stock. He exercised stock options for 50,000 shares of common stock at an exercise price of $0.67 per share, then sold 50,000 shares in open-market transactions at weighted average prices of $22.3692 and $22.7634 per share.
The sales were made under a Rule 10b5-1 trading plan adopted on May 16, 2025. Evans also received 90,000 restricted stock units under the Beam 2019 Equity Incentive Plan, vesting in four equal annual installments, and now holds 986,667 shares directly and 103,000 shares indirectly through a trust.
BEAM affiliate submitted a Form 144 notice proposing the sale of 20,000 shares of Common Stock. The filing lists the disposition method as Restricted Stock Vesting with an issuer-related transfer dated 03/31/2026. Recent reported sales by the same holder include $33,978.85 for 1,254 shares on 01/02/2026, $644,830.68 for 18,629 shares on 01/15/2026, and $46,614 for 1,371 shares on 01/22/2026. The cover records 101,856,245 shares (as of 04/02/2026).
BEAM reported an insider sale notice on Form 144 for proposed sales of Common Stock by an affiliate. The excerpt shows a restricted stock vesting event of 26,250 shares dated 03/31/2026 and a listed sale by Giuseppe Ciaramella of 35,000 shares for $1,120,041.49.